|Study Description:||The goal of this study is to learn if PCI-32765 (also called Ibrutinib or |
IMBRUVICA®) given 1 time a day is tolerable by looking at the side effects for
patients that have taken PCI-32765 in a previous study. Researchers also want
to learn if PCI-32765 can help to control the disease.
PCI-32765 is a type of drug called a kinase inhibitor. Kinases are proteins
inside cells that help cells live and grow. The specific kinase blocked by
the study drug is believed to help blood cancer cells live and grow. By
blocking the activity of this specific kinase, it is possible that the study
drug may kill the cancer cells or stop them from growing.